We are live on ! Find out more
ARNA

Arena Pharmaceuticals Inc
ARNA

Delisted

ARNA was delisted on the 10th of March, 2022.

Back to rankings

1 hedge funds and large institutions have $0 invested in Arena Pharmaceuticals Inc in 2022 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 312 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 316 → 1 (-315)

100% less funds holding in top 10

Funds holding in top 10: 7 → 0 (-7)

100% less capital invested

Capital invested by funds: $4.86B → $0 (-$4.86B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 312

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
1
Holders Change
-315
Holders Change %
-99.68%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
-7
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
312
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$530M
2
BlackRock
BlackRock
New York
-$452M
3
Wellington Management Group
Wellington Management Group
Massachusetts
-$361M
4
State Street
State Street
Massachusetts
-$213M
5
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$167M
Name Holding Trade Value Shares
Change 		Change in
Stake
PCM
226
Penserra Capital Management
California
– -$445K -4,791 Closed
DTL
227
Dynamic Technology Lab
Singapore
– -$429K -4,613 Closed
DT
228
Diversified Trust
Tennessee
– -$422K -4,545 Closed
GCP
229
GSA Capital Partners
United Kingdom
– -$422K -4,542 Closed
PCM
230
Prelude Capital Management
New York
– -$421K -4,532 Closed
HKAM
231
Horizon Kinetics Asset Management
New York
– -$418K -4,500 Closed
Squarepoint
232
Squarepoint
New York
– -$409K -4,401 Closed
B
233
Bailard
California
– -$390K -4,200 Closed
AC
234
Allstate Corporation
Illinois
– -$382K -4,107 Closed
JCM
235
Jacobi Capital Management
Pennsylvania
– -$374K -4,020 Closed
QOP
236
Quinn Opportunity Partners
Virginia
– -$372K -4,000 Closed
BC
237
Bridgefront Capital
Texas
– -$371K -3,987 Closed
PCM
238
Princeton Capital Management
New Jersey
– -$365K -3,923 Closed
JMPWA
239
JP Morgan Private Wealth Advisors
California
– -$336K -3,614 Closed
OPCM
240
Osborne Partners Capital Management
California
– -$324K -3,489 Closed
EFM
241
E Fund Management
China
– -$323K -3,473 Closed
SG Americas Securities
242
SG Americas Securities
New York
– -$316K -3,403 Closed
AC
243
Apogem Capital
New York
– -$314K -3,378 Closed
Axa
244
Axa
France
– -$307K -3,300 Closed
Canada Life
245
Canada Life
Manitoba, Canada
– -$303K -3,277 Closed
Franklin Resources
246
Franklin Resources
California
– -$304K -3,275 Closed
VF
247
Virtu Financial
New York
– -$274K -2,951 Closed
X
248
Xponance
Pennsylvania
– -$274K -2,951 Closed
Mackenzie Financial
249
Mackenzie Financial
Ontario, Canada
– -$267K -2,877 Closed
CAN
250
Cetera Advisor Networks
California
– -$267K -2,873 Closed
8 9
10
11 12

ARNA Hedge Fund Activity: Q1 2022 in Review

1 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Arena Pharmaceuticals Inc (ARNA) for Q1 2022, worth a combined $0 — down 100% from $4.86B a quarter earlier.

Sellers outnumbered buyers: 312 funds closed out of ARNA and 0 opened new positions — a net loss of 312 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was Vanguard Group, exiting entirely with an estimated $530M sold.

  • 1 institutional investor held Arena Pharmaceuticals Inc (ARNA) as of Q1 2022, down from 316 in Q4 2021.
  • Funds reported $0 of Arena Pharmaceuticals Inc stock for Q1 2022, down 100% quarter-over-quarter.
  • 0 funds opened new Arena Pharmaceuticals Inc positions in Q1 2022 and 312 closed out, a net change of -312 holders.
  • The largest Arena Pharmaceuticals Inc seller in Q1 2022 was Vanguard Group, an estimated $530M sold.

Based on aggregated 13F filings for Q1 2022.